Literature DB >> 24101097

Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.

Xiaoxia Liu1, Lingling Cao, Jinsong Ni, Ning Liu, Xiaoming Zhao, Yanfang Wang, Lin Zhu, Lingyao Wang, Jin Wang, Ying Yue, Yong Cai, Jingji Jin.   

Abstract

Human BCCIP, a protein which interacts with BRCA2 and CDKN1A (Cip1, p21), has been implicated in many cellular processes including cell cycle regulation, DNA recombination and damage repair, telomere maintenance, embryonic development and genomic stability. BCCIP gene expression, which is an important BRCA2 cofactor in tumor suppression, has been identified in some primary cancers. Thus, we investigated the role of BCCIP expression in a large sample of clinically diagnosed primary ovarian cancer, renal cell carcinoma (RCC) and colorectal cancer (CRC) tissues. Using clinically diagnosed frozen primary cancer tissues, quantitative PCR (qPCR), western blot analysis (WB) and immunohistochemical staining (IHC) approaches were used to detect and measure gene expression. Reduced BCCIP gene expression in ovarian cancer, RCC and CRC tissues occurred in 74, 89 and 75% of tissue samples, respectively. qPCR analysis of mRNA expression in 54 ovarian cancer, 50 RCC and 44 CRC samples revealed significant (>2-fold decreased) BCCIP downregulation in 56, 70 and 46% of tissue samples, respectively. Although BCCIP expression in three different tumor tissues decreased, the relationship between BCCIP expression and clinicopathological features of each cancer was distinct. Compared to normal tissues, BCCIP expression in ovarian cancers was significantly downregulated in serous, endometrioid and mucinous carcinomas. Downregulation of BCCIP expression was strongly associated with clear cell RCC (ccRCC) and Fuhrman tumor grading, but significant differences in BCCIP expression between CRC and matched normal tissues occurred only in male CRC tissues (p<0.05) and in tissue with a T4 tumor stage (p<0.01). Thus, BCCIP protein was chiefly reduced in ovarian cancer and RCC tissue samples (p<0.05). BCCIP gene expression was downregulated in human ovarian cancer, RCC and CRC tissues, suggesting a role for the gene in the pathogenesis of these cancers.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24101097     DOI: 10.3892/ijo.2013.2124

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  Expression pattern of BCCIP in hepatocellular carcinoma is correlated with poor prognosis and enhanced cell proliferation.

Authors:  Zhipeng Lin; Baoying Hu; Wenkai Ni; Xiaofei Mao; Huiling Zhou; Jiale Lv; Bihui Yin; Zhongyi Shen; Miaomiao Wu; Wensen Ding; Mingbing Xiao; Runzhou Ni
Journal:  Tumour Biol       Date:  2016-11-10

2.  High Expression of BCCIP β Can Promote Proliferation of Esophageal Squamous Cell Carcinoma.

Authors:  Lingling Chen; Sujie Ni; Mei Li; Chaoyan Shen; Zhipeng Lin; Yu Ouyang; Fei Xia; Li Liang; Wenyan Jiang; Runzhou Ni; Jianguo Zhang
Journal:  Dig Dis Sci       Date:  2016-12-19       Impact factor: 3.199

3.  Celecoxib enhances the radiosensitivity of HCT116 cells in a COX-2 independent manner by up-regulating BCCIP.

Authors:  Xiao-Ting Xu; Wen-Tao Hu; Ju-Ying Zhou; Yu Tu
Journal:  Am J Transl Res       Date:  2017-03-15       Impact factor: 4.060

4.  Spontaneous Development of Hepatocellular Carcinoma and B-Cell Lymphoma in Mosaic and Heterozygous Brca2 and Cdkn1a Interacting Protein Knockout Mice.

Authors:  Huimei Lu; Caiyong Ye; Xing Feng; Jingmei Liu; Mantu Bhaumik; Bing Xia; Chen Liu; Zhiyuan Shen
Journal:  Am J Pathol       Date:  2020-03-20       Impact factor: 4.307

5.  Subpathway Analysis based on Signaling-Pathway Impact Analysis of Signaling Pathway.

Authors:  Xianbin Li; Liangzhong Shen; Xuequn Shang; Wenbin Liu
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

6.  FH535 inhibited metastasis and growth of pancreatic cancer cells.

Authors:  Meng-Yao Wu; Rong-Rui Liang; Kai Chen; Meng Shen; Ya-Li Tian; Dao-Ming Li; Wei-Ming Duan; Qi Gui; Fei-Ran Gong; Lian Lian; Wei Li; Min Tao
Journal:  Onco Targets Ther       Date:  2015-07-06       Impact factor: 4.147

7.  Human INO80/YY1 chromatin remodeling complex transcriptionally regulates the BRCA2- and CDKN1A-interacting protein (BCCIP) in cells.

Authors:  Jiaming Su; Yi Sui; Jian Ding; Fuqiang Li; Shuang Shen; Yang Yang; Zeming Lu; Fei Wang; Lingling Cao; Xiaoxia Liu; Jingji Jin; Yong Cai
Journal:  Protein Cell       Date:  2016-08-17       Impact factor: 14.870

8.  Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma.

Authors:  Kenta Mukaihara; Yoshiyuki Suehara; Shinji Kohsaka; Daisuke Kubota; Midori Toda-Ishii; Keisuke Akaike; Tsutomu Fujimura; Eisuke Kobayashi; Takashi Yao; Marc Ladanyi; Kazuo Kaneko; Tsuyoshi Saito
Journal:  BMC Cancer       Date:  2016-03-10       Impact factor: 4.430

9.  Roles of BCCIP deficiency in mammary tumorigenesis.

Authors:  Roberto Droz-Rosario; Huimei Lu; Jingmei Liu; Ning-Ang Liu; Shridar Ganesan; Bing Xia; Bruce G Haffty; Zhiyuan Shen
Journal:  Breast Cancer Res       Date:  2017-10-18       Impact factor: 6.466

10.  The β-isoform of BCCIP promotes ADP release from the RAD51 presynaptic filament and enhances homologous DNA pairing.

Authors:  Andrew A Kelso; Steven D Goodson; Leah E Watts; LeAnna L Ledford; Sarah M Waldvogel; J Nathaniel Diehl; Shivani B Shah; Amanda F Say; Julie D White; Michael G Sehorn
Journal:  Nucleic Acids Res       Date:  2016-09-30       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.